CRESCENT BIOPHARMA, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
CRESCENT BIOPHARMA, INC. (CBIO) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-13.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2025-05-14
- CRESCENT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2024-03-31 was 0.00%.
- CRESCENT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2023-03-31 was 0.00%.
- CRESCENT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2022-03-31 was 0.00%.
- CRESCENT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2021-03-31 was 0.00%.
- CRESCENT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2024 was 0.00%.
- CRESCENT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2023 was 0.00%.
- CRESCENT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2022 was 0.00%.
- CRESCENT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2021 was 0.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month |
|---|---|---|---|---|
| 2024-12-31 | 0.00% 10-K · filed 2025-02-13 | |||
| 2024-09-30 | 0.00% 10-Q · filed 2024-11-13 | |||
| 2024-06-30 | 0.00% 10-Q · filed 2024-08-08 | |||
| 2024-03-31 | 0.00% 10-Q · filed 2025-05-14 | |||
| 2023-12-31 | 0.00% 10-K · filed 2025-02-13 | |||
| 2023-09-30 | 0.00% 10-Q · filed 2024-11-13 | |||
| 2023-06-30 | 0.00% 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | 0.00% 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | 0.00% 10-K · filed 2024-03-27 | |||
| 2022-09-30 | 0.00% 10-Q · filed 2023-11-03 | |||
| 2022-06-30 | 0.00% 10-Q · filed 2023-08-02 | |||
| 2022-03-31 | 0.00% 10-Q · filed 2023-05-03 | |||
| 2021-12-31 | 0.00% 10-K · filed 2024-03-27 | |||
| 2021-09-30 | 0.00% 10-Q · filed 2022-11-09 | |||
| 2021-06-30 | 0.00% 10-Q · filed 2022-08-03 | |||
| 2021-03-31 | 0.00% 10-Q · filed 2022-04-28 | |||
| 2020-12-31 | 0.00% 10-K · filed 2023-03-29 | |||
| 2020-09-30 | 0.00% 10-Q · filed 2021-11-02 | |||
| 2020-06-30 | 0.00% 10-Q · filed 2021-08-05 | |||
| 2020-03-31 | 0.00% 10-Q · filed 2021-05-03 | |||
| 2019-12-31 | 0.00% 10-K · filed 2022-03-03 | |||
| 2019-09-30 | 0.00% 10-Q · filed 2020-11-06 | |||
| 2019-06-30 | 0.00% 10-Q · filed 2020-07-31 | |||
| 2019-03-31 | 0.00% 10-Q · filed 2020-05-01 | |||
| 2018-12-31 | 0.00% 10-K · filed 2021-03-02 | |||
| 2018-09-30 | 0.00% 10-Q · filed 2019-11-07 | |||
| 2018-06-30 | 0.00% 10-Q · filed 2019-08-01 | |||
| 2018-03-31 | 0.00% 10-Q · filed 2019-05-02 | |||
| 2017-12-31 | 0.00% 10-K · filed 2020-02-28 | |||
| 2016-12-31 | 0.00% 10-K · filed 2019-03-06 | |||
| 2016-06-30 | 0.00% 10-Q · filed 2016-08-04 | |||
| 2016-03-31 | 0.00% 10-Q · filed 2016-05-04 | |||
| 2015-06-30 | 0.00% 10-Q · filed 2016-08-04 | |||
| 2015-03-31 | 0.00% 10-Q · filed 2016-05-04 | |||
| 2014-09-30 | 0.00% 10-Q · filed 2014-10-31 | |||
| 2014-06-30 | 0.00% 10-Q · filed 2014-07-31 | |||
| 2014-03-31 | 0.00% 10-Q · filed 2014-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |